LENZ Therapeutics, Inc. (LENZ)

NASDAQ: LENZ · IEX Real-Time Price · USD
21.81
+5.07 (30.29%)
At close: Mar 27, 2024, 4:00 PM
21.99
+0.18 (0.83%)
Pre-market: Mar 28, 2024, 7:05 AM EDT

Company Description

As of March 21, 2024, Graphite Bio, Inc. was acquired by LENZ Therapeutics, Inc., in a reverse merger transaction.

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States.

The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene.

It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme.

The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020.

Graphite Bio, Inc. was incorporated in 2017 and is based in South San Francisco, California.

LENZ Therapeutics, Inc.
LENZ Therapeutics logo
Country Canada
Founded 2019
IPO Date Jun 25, 2021
Industry Biotechnology
Sector Healthcare
Employees 6

Contact Details

Address:
445 Marine View Ave Suite 320
Del Mar, California 92014
United States
Phone 858-925-7000

Stock Details

Ticker Symbol LENZ
Exchange NASDAQ
Fiscal Year January - December
IPO Price $17.00
CIK Code 0001815776
ISIN Number US38870X1046
Employer ID 84-4867570
SIC Code 2836

Key Executives

Name Position
Kimberlee Cobleigh Drapkin CPA President, Chief Executive Officer, Chief Operating Officer, Principal Executive, Financial and Accounting Officer and Director
Dr. Matthew Porteus M.D., Ph.D. Academic Founder and Director
Stephanie Yao Vice President of Communications and Investor Relations
Dr. Christine Garrett P.M.P., Ph.D. Chief Strategy Officer

Latest SEC Filings

Date Type Title
Mar 25, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Mar 25, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Mar 25, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Mar 22, 2024 8-K Current Report
Mar 19, 2024 8-K Current Report
Mar 14, 2024 8-K Current Report
Mar 8, 2024 425 Filing
Mar 8, 2024 8-K Current Report
Mar 5, 2024 425 Filing
Mar 5, 2024 8-K Current Report